Symbiotec Pharmalab Key Ratios
NSE: SYMBIOTEC | BSE: 544889
₹1,198.00
₹21.25
(1.81%)
As on 01-Oct-2026IST
Market cap
₹7,706 Cr
Revenue (TTM)
₹869 Cr
P/E Ratio
70.1
P/B Ratio
5.1
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | 7.37 | 15.65 | 15.34 | 6.55 |
| EBIT | -- | -50.75 | 16.14 | 65.33 | 1.47 |
| Net Profit | -- | -53.02 | 13.55 | 67.26 | -2.41 |
| EPS | -- | -59.05 | -1.03 | 59.77 | -4.92 |
| Book Value | -- | -- | 23.55 | 17.24 | 13.98 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Mar-26 | Mar-25 | Mar-24 |
| EBIT-Margin
| 12.55 | 16.78 | 21.33 | 21.24 | 18.60 |
| Net Margin
| 6.18 | 10.92 | 12.60 | 12.80 | 13.83 |
| Return on equity
| 6.13 | 11.31 | 11.22 | 12.69 | 14.97 |
| Return on Capital
| 9.24 | 13.16 | 12.41 | 14.14 | 15.42 |
| Return on Assets
| 4.50 | 6.88 | 6.54 | 6.73 | 8.76 |
| Debt to Equity (x)
| -- | -- | 0.34 | 0.67 | 0.35 |
Profitability
ROCE
12.41
Lower than Peers by 1.63
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Symbiotec Pharmalab
|
12.41
|
14.14
|
15.42
|
6.18
|
17.64
|
|
Peer Median
|
14.03
|
16.46
|
15.49
|
17.37
|
--
|
ROE
11.22
Lower than Peers by 2.23
Profit after tax / Average Net worth * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Symbiotec Pharmalab
|
11.22
|
12.69
|
14.97
|
3.85
|
13.81
|
|
Peer Median
|
13.45
|
13.87
|
14.72
|
15.70
|
--
|
ROA
6.54
Lower than Peers by 1.40
Profit after tax / Average Total assets * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Symbiotec Pharmalab
|
6.54
|
6.73
|
8.76
|
2.60
|
9.76
|
|
Peer Median
|
7.94
|
8.04
|
7.19
|
9.43
|
--
|
EBIT Margin
21.33
Higher than Peers by 0.02
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Symbiotec Pharmalab
|
21.33
|
21.24
|
18.60
|
7.24
|
15.49
|
|
Peer Median
|
21.31
|
10.05
|
10.28
|
13.90
|
--
|
Net Margin
12.60
Higher than Peers by 0.72
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Symbiotec Pharmalab
|
12.60
|
12.80
|
13.83
|
4.10
|
11.29
|
|
Peer Median
|
11.88
|
9.11
|
6.78
|
10.91
|
--
|
Cash Profit Margin
18.57
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Symbiotec Pharmalab
|
18.57
|
18.39
|
19.20
|
9.04
|
15.12
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
15.65
Lower than Peers by 0.27
Year on year growth in net sales
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Symbiotec Pharmalab
|
15.65
|
4.93
|
26.43
|
-16.91
|
7.73
|
|
Peer Median
|
15.92
|
7.17
|
10.56
|
12.63
|
--
|
EBIT Growth
16.14
Lower than Peers by 8.62
Year on year growth in operating profit (EBIT)
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Symbiotec Pharmalab
|
16.14
|
19.81
|
224.78
|
-61.16
|
-38.71
|
|
Peer Median
|
24.76
|
12.05
|
6.17
|
-2.90
|
--
|
Net Profit Growth
13.55
Lower than Peers by 10.70
Year on year growth in profit after tax
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Symbiotec Pharmalab
|
13.55
|
-3.27
|
326.02
|
-69.61
|
-37.75
|
|
Peer Median
|
24.25
|
22.15
|
27.97
|
-14.10
|
--
|
EPS Growth
-1.03
Lower than Peers by 27.14
Year on year growth in earnings per share
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Symbiotec Pharmalab
|
-1.03
|
-3.27
|
326.02
|
-69.71
|
-37.11
|
|
Peer Median
|
26.11
|
8.80
|
--
|
-3.68
|
--
|
Book Value Growth
41.75
--
Year on year growth in book value per share
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Symbiotec Pharmalab
|
41.75
|
13.36
|
15.05
|
3.81
|
15.02
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.34
Higher than Peers by 0.17
Total debt / Net worth
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Symbiotec Pharmalab
|
0.34
|
0.67
|
0.35
|
0.35
|
0.11
|
|
Peer Median
|
0.17
|
0.03
|
0.05
|
0.14
|
--
|
Short term debt to equity ratio
0.25
--
(Short term borrowings / Net worth)
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Symbiotec Pharmalab
|
0.25
|
0.28
|
0.07
|
0.17
|
0.11
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.92
Lower than Peers by 1.31
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Symbiotec Pharmalab
|
0.92
|
1.04
|
1.45
|
1.75
|
2.25
|
|
Peer Median
|
2.23
|
2.20
|
1.93
|
1.82
|
--
|
Quick Ratio
0.47
Lower than Peers by 1.35
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Symbiotec Pharmalab
|
0.47
|
0.49
|
0.49
|
0.69
|
0.95
|
|
Peer Median
|
1.82
|
1.72
|
1.59
|
1.30
|
--
|
Interest Coverage
6.87
Lower than Peers by 4.44
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Symbiotec Pharmalab
|
6.87
|
9.69
|
17.45
|
5.70
|
34.57
|
|
Peer Median
|
11.31
|
12.28
|
12.45
|
16.98
|
--
|
Operating Efficiency
Debtors to sales
22.73
Lower than Peers by 8.09
Debtors outstanding / Net Sales * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Symbiotec Pharmalab
|
22.73
|
23.37
|
17.55
|
19.76
|
21.05
|
|
Peer Median
|
30.82
|
26.23
|
23.97
|
24.57
|
--
|
Asset Turnover
0.52
Lower than Peers by 0.20
Sales / Average Total Assets
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Symbiotec Pharmalab
|
0.52
|
0.53
|
0.63
|
0.64
|
0.86
|
|
Peer Median
|
0.72
|
0.74
|
0.88
|
0.82
|
--
|
Receivable days
77.53
--
Average Debtors / Sales * 365
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Symbiotec Pharmalab
|
77.53
|
72.30
|
59.95
|
81.07
|
70.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
103.51
--
Average Inventory / Sales * 365
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Symbiotec Pharmalab
|
103.51
|
143.31
|
146.23
|
155.32
|
126.16
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
131.22
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Symbiotec Pharmalab
|
131.22
|
193.98
|
178.64
|
109.67
|
104.87
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
49.82
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Symbiotec Pharmalab
|
49.82
|
21.63
|
27.55
|
126.72
|
91.30
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Symbiotec Pharmalab
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
57.68
|
39.17
|
40.74
|
25.97
|
--
|
Price / Book Value
--
--
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Symbiotec Pharmalab
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
4.99
|
3.61
|
3.87
|
2.79
|
--
|
EV/EBITDA
1.61
Lower than Peers by 45.01
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Symbiotec Pharmalab
|
1.61
|
2.54
|
1.40
|
2.94
|
0.48
|
|
Peer Median
|
46.62
|
28.79
|
25.41
|
15.07
|
--
|
Market Cap
--
--
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Symbiotec Pharmalab
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
6,180
|
3,944
|
2,959
|
3,742
|
--
|
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
